Compare JetBlue Airways Corporation (JBLU) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JetBlue Airways Corporation vs Merck & Co., Inc. — how do they compare? JetBlue Airways Corporation trades at $5.34 (market cap $2.03B), while Merck & Co., Inc. trades at $125.97 (market cap $307.25B). The key difference: Merck & Co., Inc. is far larger — about 151.4× JetBlue Airways Corporation's market cap, and Merck & Co., Inc. pays a 2.73% dividend while JetBlue Airways Corporation pays none. Which is the better fit depends on your goals.
| JBLU | MRK | |
|---|---|---|
Market Cap | $2.03B | $307.25B |
Sector | Industrials | Health |
52-Week High | $6.46 | $129.52 |
52-Week Low | $4.03 | $77.60 |
Enterprise Value | $9.19B | $350.66B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JetBlue (JBLU) trades at $5.35, down 1.29% on the day, with mixed technical signals showing a neutral overall bias. The company faces fundamental challenges with negative profitability metrics, including a -7.78% net income margin and -33.51% ROE, despite reasonable valuation ratios like P/S of 0.22. Recent developments include securing Spirit Airlines' LaGuardia Airport slots and launching new payment partnerships, providing potential operational catalysts amid ongoing losses.
The outlook remains challenging with persistent net losses and high debt levels, though strategic expansions and new financing options offer growth potential. Key risks include fuel cost volatility and competitive pressures, while analyst sentiment is cautious with a $5.12 consensus target suggesting limited upside from current levels.
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
